The stock price of Quince Therapeutics Inc (NASDAQ: QNCX) has plunged by -10.84 when compared to previous closing price of 1.66, but the company has seen a -14.45% decline in its stock price over the last five trading sessions. businesswire.com reported 2024-11-13 that SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $QNCX #biotech–Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the third quarter ended September 30, 2024. Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, “We are pleased to report accelerating enrollment of ou.
Is It Worth Investing in Quince Therapeutics Inc (NASDAQ: QNCX) Right Now?
The 36-month beta value for QNCX is also noteworthy at 0.62. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for QNCX is 32.81M, and at present, short sellers hold a 7.31% of that float. The average trading volume of QNCX on January 22, 2025 was 608.82K shares.
QNCX’s Market Performance
The stock of Quince Therapeutics Inc (QNCX) has seen a -14.45% decrease in the past week, with a -19.57% drop in the past month, and a 86.66% gain in the past quarter. The volatility ratio for the week is 8.11%, and the volatility levels for the past 30 days are at 8.45% for QNCX. The simple moving average for the past 20 days is -17.55% for QNCX’s stock, with a 36.30% simple moving average for the past 200 days.
QNCX Trading at -20.08% from the 50-Day Moving Average
After a stumble in the market that brought QNCX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.59% of loss for the given period.
Volatility was left at 8.45%, however, over the last 30 days, the volatility rate increased by 8.11%, as shares sank -20.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.71% upper at present.
During the last 5 trading sessions, QNCX fell by -14.45%, which changed the moving average for the period of 200-days by +40.95% in comparison to the 20-day moving average, which settled at $1.7950. In addition, Quince Therapeutics Inc saw -20.86% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at QNCX starting from Thye Dirk, who purchase 77,000 shares at the price of $0.70 back on Aug 30 ’24. After this action, Thye Dirk now owns 843,941 shares of Quince Therapeutics Inc, valued at $53,900 using the latest closing price.
Thye Dirk, the CEO AND CHIEF MEDICAL OFFICER of Quince Therapeutics Inc, purchase 77,500 shares at $0.69 during a trade that took place back on Aug 29 ’24, which means that Thye Dirk is holding 766,941 shares at $53,475 based on the most recent closing price.
Stock Fundamentals for QNCX
Current profitability levels for the company are sitting at:
- -1349.19 for the present operating margin
- -9.78 for the gross margin
The net margin for Quince Therapeutics Inc stands at -1479.56. The total capital return value is set at -0.4. Equity return is now at value -83.18, with -50.27 for asset returns.
Based on Quince Therapeutics Inc (QNCX), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at -1.97. The debt to equity ratio resting at 0.34. The interest coverage ratio of the stock is -106.98.
Currently, EBITDA for the company is -31.26 million with net debt to EBITDA at -0.37. When we switch over and look at the enterprise to sales, we see a ratio of 2163.82. The receivables turnover for the company is 0.04for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.53.
Conclusion
In summary, Quince Therapeutics Inc (QNCX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
